Delhi govt sets up control rooms to manage coronavirus-related drugs

The Delhi government has set up two control rooms to monitor and manage the supply of "Covid-19 management drugs" amid a massive rise in coronavirus cases in the national capital

vaccination, coronavirus, covid-19, vaccines, storage
Press Trust of India New Delhi
2 min read Last Updated : Apr 19 2021 | 12:11 PM IST

The Delhi government has set up two control rooms to monitor and manage the supply of "COVID-19 management drugs" amid a massive rise in coronavirus cases in the national capital.

Delhi on Sunday recorded the biggest jump in its daily COVID-19 tally with 25,462 fresh cases, while the positivity rate shot up to 29.74 per cent -- meaning almost every third sample being tested in the city is turning out to be positive.

In an order, the government's Drugs Control Department said that the step has been taken to address reports of "acute shortage of COVID-19 management drugs due to a sudden rise in COVID-19 cases in Delhi".

"In view to counter this situation and to facilitate the general public at large, the Drugs Control Department. Govt of NCT of Delhi has set up two control rooms," the order dated April 13 said.

For East, North East, South, Central, New Delhi and North districts, the Karkardooma Head Office will serve as the control room and operate the helpline number -- 011-22393705, according to the order.

The Lawrence Road Zonal Office is the second control room and it will serve the North West, South West, and West districts. It can be reached at helpline number-- 011-27100164, it said.

The department said that manufacturing companies can also be reached through their individual helpline numbers.

"Every attempt is being made to make available COVID management drugs in all major hospitals and company distribution outlets for which companies have also provided their helpline numbers, who can be approached along with documentary details of the hospitalization of patient, hospital prescription, COVID positive report and Aadhar card," it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus TestsDelhi

First Published: Apr 19 2021 | 12:08 PM IST

Next Story